Recherches "plusieurs pathologies" CIRCA-HPV (IC 2017-01) Circulating Tumor DNA for the Early Detection of HPV-positive Pelvic Cancer Relapses. Paris, Saint-Cloud BRUNO BUECHER
Sein Néoadjuvant ROSALINE Neoadjuvant Study of Targeting ROS1 in Combination With Endocrine Therapy in Invasive Lobular Carcinoma of the Breast Paris FLORENCE COUSSY
Sein Néoadjuvant Neo-CheckRay Neo-adjuvant Chemotherapy Combined With Stereotactic Body Radiotherapy to the Primary Tumour +/- Durvalumab, +/- Oleclumab in Luminal B Breast Cancer: a Phase ll Randomised Trial. Paris EMANUELA ROMANO
Appareil Digestif ProActIF-01 ProActIF-01 Trial: Randomized phase II study of evaluation of an Individualized Program of nutrition and adapted physical Activity in Frail patients with advanced lung or digestive cancers Paris, Saint-Cloud
Sein métastatique RH+ ESTROTIMP Impact of 18F-FES PET on the Therapeutic Treatment of Patients With Metastatic Breast Cancer (ESTROTIMP) Paris, Saint-Cloud
Sein métastatique RH+ CT7001_003 (SUMIT ELA) A Phase 1b/2 Open-label Study of Samuraciclib in Combination with Elacestrant in;Participants with Metastatic or Locally Advanced Hormone Receptor-positive and Human;Epidermal Growth Factor Receptor 2-negative Breast Cancer. Saint-Cloud FRANCOIS-CLEMENT BIDARD
Appareil Digestif ADAGE - Prodige 34 Randomised Phase III Study Evaluating Adjuvant Chemotherapy After Resection of Stage III Colonic Adenocarcinoma in Patients of 70 and Over. Saint-Cloud
Sein métastatique RH+ AIPAC AIPAC (Active Immunotherapy PAClitaxel): A Multicentre, Phase IIb, Randomised,Double Blind, Placebo-controlled Study in Hormone Receptor-positive Metastatic Breast Carcinoma Patients Receiving IMP321 (LAG-3Ig Fusion Protein) or Placebo as Adjunctive to a Standard Chemotherapy Treatment Regimen of Paclitaxel Saint-Cloud ETIENNE BRAIN
Appareil Digestif AMEBICA - Prodige 38 Randomised Phase II/III Study, Assessing the Safety and Efficacy of Modified Folfirinox Versus Gemcis in Locally Advanced, Unresectable and/or Metastatic Bile Duct Tumours. Saint-Cloud
Sein métastatique RH+ BYLieve (CBYL719X402) A Phase II, Multicenter, Open-label, Two-cohort, Non-comparative Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole in Patients With PIK3CA Mutant, Hormone Receptor (HR) Positive, HER2-negative Advanced Breast Cancer (aBC), Who Have Progressed on or After CDK 4/6 Inhibitor Treatment Saint-Cloud FLORENCE LEREBOURS